Clin2
NCT07183748Worth exploringRecruiting

Psilocybin microdosing plus therapy for hard-to-treat depression

Treatment Resistant Depression

Treatments studied

Part of Mental health clinical trials.

This trial tests whether taking very small, repeated doses of psilocybin (a substance found in magic mushrooms) along with talk therapy can help people with depression that hasn't gotten better with other treatments. You'll need to stop your current depression medications and avoid drugs or alcohol for the study period.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
20 people
Ages
18 years to 65 years
Study type
Interventional

Who can take part

  • You are between 18 and 65 years old.
  • You have been diagnosed with major depression that hasn't improved with other treatments.
  • You are willing to stop taking psychiatric medications 2 weeks before the study starts and for the whole study.
  • You agree to avoid alcohol, cannabis, and all recreational drugs during the study.
  • You can commit to all study visits and follow-ups, and provide a contact for someone close to you in case of an emergency.
  • You are not pregnant or breastfeeding, and if you could become pregnant, you agree to use birth control.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06512220Recruiting· Phase 2
Psilocybin for treatment-resistant depression brain imaging study

This study tests whether a psilocybin-based treatment can help people with depression that has not improved after trying several antidepressants. You will receive the study treatment and have brain scans to see how it affects brain connections.

Toronto, Ontario
NCT06378229Recruiting· Phase 2
Psilocybin for hospitalized treatment-resistant depression

This trial tests whether a single dose of psilocybin can help hospitalized patients with tough-to-treat depression. It focuses on people who haven't improved with standard antidepressants and need a new option.

Ghent, Oost-Vlaanderen
NCT06132178Recruiting· Phase 2
Psilocybin and rTMS for hard-to-treat depression

This study tests whether a combination of psilocybin (a psychedelic substance) and transcranial magnetic stimulation (rTMS, a noninvasive brain stimulation) can help people with treatment-resistant depression. It involves daily visits to the research center for about 2 weeks.

Austin, Texas
NCT07499583Not yet recruiting· Phase 1/Phase 2
Psilocybin therapy for depression and substance use in veterans and first responders

This trial tests whether psilocybin-assisted psychotherapy can help veterans and first responders with treatment-resistant depression and a co-occurring substance use disorder. It aims to see if this approach reduces depression and substance use.

Indianapolis, Indiana
NCT07281352Recruiting· Phase 1/Phase 2
Psilocybin therapy for depression

This study tests if psilocybin (a psychedelic) combined with cognitive behavioral therapy (CBT) can help people with major depression. You would receive the psilocybin in a supervised setting and have talk therapy before and after.

Los Angeles, California
NCT06247839Recruiting· Phase 3
Psilocybin for depression: changing self-focus

This trial tests whether a single dose of psilocybin can help people with treatment-resistant depression by changing how they focus on themselves. It aims to understand how psilocybin affects brain activity and self-related thinking.

Charlestown, Massachusetts

Hear when a new Treatment Resistant Depression trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.